ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program

Go back to ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
IMMUNOCELLULAR THERAPEUTICS, LTD. (AMEX: IMUC) Delayed: 0.22 --0 (-0%)
Previous Close $0.22    52 Week High $0.53 
Open $0.22    52 Week Low $0.08 
Day High $0.22    P/E N/A 
Day Low $0.22    EPS $-0.14 
Volume 22